Ang II Controls the Expression of Mapkap1 by miR-375 and Affects theFunction of Islet β Cells

Xiuhong Lin, Lin Cheng, Yan Wan, Yuerong Yan, Zhuo Zhang, Xiaohui Li, Jiayun Wu, Xiaoyi Wang, Mingtong XuEndocrine 2023 · DOI

TL;DR

This study reveals a novel regulatory pathway where Angiotensin II (Ang II) exacerbates islet β-cell dysfunction by upregulating miR-375, which in turn downregulates Mapkap1. This mechanism, impacting Akt phosphorylation, offers new insights into diabetes pathogenesis and potential therapeutic targets.

What Problem Does This Paper Address?

Diabetes, a growing global health crisis, is characterized by islet β-cell damage. While the renin-angiotensin system (RAS), particularly Ang II, is implicated in islet function and injury, the precise molecular mechanisms remain unclear. Specifically, how Ang II influences the intricate signaling pathways within islet β-cells that govern their survival and function is a key question. This paper aims to elucidate the role of a specific microRNA, miR-375, in mediating Ang II's effects on islet β-cells, focusing on its downstream targets and their impact on crucial cellular processes.

Methods

The researchers employed a multi-pronged approach to investigate the Ang II-miR-375-Mapkap1 axis:

  • Cell Culture and Transfection: MIN6 cells, a mouse insulin-secreting β-cell line, were used as the primary model. They utilized miR-375 mimics and inhibitors to either overexpress or suppress miR-375 activity. Transfection was achieved using lipofection.
  • Molecular Biology Techniques:
    • RT-PCR: Used to quantify the expression levels of miR-375 and Mapkap1 mRNA.
  • Western Blot: Employed to measure protein levels, specifically focusing on Mapkap1 and phosphorylated forms of key signaling molecules like IR-β and Akt (Akt-Ser473).
  • Dual-Luciferase Reporter Assay: This was a crucial technique to validate the direct interaction between miR-375 and the 3'UTR of Mapkap1, confirming Mapkap1 as a direct target.
  • Functional Assays:
    • Annexin V/PI Staining Flow Cytometry: Assessed cell apoptosis.
  • Cell Counting Kit-8 (CCK-8): Measured cell proliferation and viability.
  • Radioimmunoassay: Quantified insulin secretion from the MIN6 cells.
  • Bioinformatics: Used to predict potential miR-375 target genes, with Mapkap1 being identified as a strong candidate.

Datasets

Not discussed in the paper. The study primarily relies on in vitro experiments using the MIN6 cell line.

Key Insights and Ideas

  • miR-375 as a Mediator of Ang II's Harmful Effects: The study strongly suggests that miR-375 acts as a key intermediary through which Ang II negatively impacts islet β-cells. Ang II increases miR-375 levels, which then contributes to reduced cell viability and increased apoptosis.
  • Mapkap1 as a Direct Target of miR-375: Through a combination of bioinformatics predictions and experimental validation (dual-luciferase assay), Mapkap1 was identified as a direct target of miR-375. This is a significant finding, linking a specific microRNA to a protein involved in crucial cellular signaling.
  • The mTORC2-Akt Pathway is Involved: The research points towards the mTORC2-Akt pathway as the downstream effector. miR-375's regulation of Mapkap1 appears to influence Akt phosphorylation (specifically Akt-Ser473), a critical step in insulin signaling and cell survival.
  • Therapeutic Potential of Targeting this Axis: The findings open avenues for developing miRNA-targeted therapies to protect islet β-cells from Ang II-induced damage, offering a new perspective beyond traditional diabetes treatments.

Key Results

  • Ang II Upregulates miR-375: Treatment of MIN6 cells with Ang II led to a significant increase in miR-375 expression.
  • miR-375 Mimics Increase Apoptosis and Decrease Viability: Transfecting MIN6 cells with miR-375 mimics, especially in the presence of Ang II, significantly increased apoptosis and decreased cell viability. Conversely, miR-375 inhibitors showed protective effects.
  • Mapkap1 is Downregulated by miR-375: Overexpression of miR-375 (mimic transfection) led to a significant decrease in Mapkap1 protein levels, while inhibition of miR-375 (inhibitor transfection) increased Mapkap1 protein. Importantly, mRNA levels of Mapkap1 were not significantly affected, suggesting post-transcriptional regulation.
  • Ang II Downregulates Mapkap1 Protein: Ang II treatment of MIN6 cells resulted in a dose- and time-dependent decrease in Mapkap1 protein levels, correlating with increased miR-375.
  • miR-375 Affects Akt Phosphorylation: miR-375 mimic transfection reduced Akt-Ser473 phosphorylation, while miR-375 inhibitor transfection increased it, particularly in the context of Ang II treatment.
  • Mapkap1 Inhibition Mimics Ang II Effects: Silencing Mapkap1 expression using siRNA led to increased apoptosis, decreased insulin secretion, and reduced Akt-Ser473 phosphorylation, mirroring some of the effects of Ang II.
  • TSB-Mapkap1 Rescues Ang II Effects: Blocking miR-375's interaction with Mapkap1 using a target site blocker (TSB-Mapkap1) partially reversed Ang II's negative effects on Mapkap1 protein levels, apoptosis, and insulin secretion.

Limitations and Future Work

  • In Vitro Model: The study primarily uses the MIN6 cell line. While a valuable model, future work should validate these findings in primary islet cells and in vivo models to confirm their physiological relevance.
  • Specific Mechanism of mTORC2-Akt Involvement: While the study implicates the mTORC2-Akt pathway, the precise molecular details of how Mapkap1's interaction with miR-375 influences mTORC2 and subsequently Akt phosphorylation require further in-depth investigation.
  • Broader Physiological Context: The study focuses on Ang II. Investigating how other components of the RAS system interact with miR-375 and Mapkap1 in islet β-cells would provide a more comprehensive understanding.
  • Clinical Translation: Translating these findings into clinical applications for diabetes prevention or treatment will require extensive further research, including preclinical and clinical trials.

Summary updated

Abstract

The effects of Ang II on mouse islet β cells were mediated by miR-375 through miR- 375/Mapkap 1 axis. This targeted regulation may occur by affecting Akt phosphorylation of β cells. These results may provide new ideas and a scientific basis for further development of miRNA-targeted islet protection measures.
BibTeX
@inproceedings{lin2023ang,
  author = {Xiuhong Lin and Lin Cheng and Yan Wan and Yuerong Yan and Zhuo Zhang and Xiaohui Li and Jiayun Wu and Xiaoyi Wang and Mingtong Xu and Xiaoyi Wang and Mingtong Xu and Mingtong Xu},
  title = {{Ang II Controls the Expression of Mapkap1 by miR-375 and Affects theFunction of Islet β Cells}},
  booktitle = {Endocrine},
  year = {2023},
  doi = {10.2174/1871530323666230206121715},
}
Figure